Merck KANDLELIT Trials Spark Hope For Hard-To-Treat Cancers Merck shared safety and efficacy results of MK-1084; either as monotherapy or in combinations, it demonstrated a manageable safety profile.
Summit Therapeutics, A Top 1% Biotech, Plummets On A High-Profile Failure There's a long history of anti-PD-1 and anti-VEGF drugs working to slow progression, but not improve overall survival.
2 Cash-Producing Stocks for Long-Term Investors and 1 to Steer Clear Of A company that generates cash isn’t automatically a winner.
Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.
Merck, Daiichi Sankyo Pull FDA Application For Lung Cancer Therapy: Retail Terms It A ‘Huge Flop’ The decision is based on results from a late-stage trial in which the drug failed to prolong patients' lives, the companies stated.
Keros Therapeutics Stops PAH Drug Development, Shrinks Workforce By 45% Keros ends PAH development of cibotercept after Phase 2 safety issues, including pericardial effusions, and plans to cut 45% of workforce amid review.
MERCK & CO. INC. (NYSE:MRK) - A Reliable Dividend Stock with Strong Fundamentals MERCK & CO. (
NYSE:MRK ) offers a strong 4.2% dividend yield, consistent growth, and solid financial health, making it a top pick for dividend investors.
Merus Skyrockets On 'Unprecedented' Cancer Results, Slamming Bicara Therapeutics The companies are duking it out for the best treatment for head-and-neck cancer. One clearly has the edge.
3 Dow Jones Stocks on Our Watchlist The Dow Jones (^DJI) includes some of the most reliable stocks in the market, and while not all are equal, a few continue to shine.
These companies are leveraging their strengths to maintain leadership and reward investors.
Moderna Stock Looks Ripe for a Short Squeeze Moderna stock has made single-digit gains in the last month, and high short interest suggests that any bullish news could cause a short squeeze
MERCK & CO. INC. (NYSE:MRK) - A Strong Value Candidate in Pharmaceuticals MERCK & CO. (
NYSE:MRK ) offers strong value with a low P/E ratio, high profitability, and a reliable dividend. A solid pick for value investors in the pharmaceutical sector.
Merck Data Shows Positive Outcomes For Ovarian Cancer Patients Treated With Keytruda Merck's Phase 3 trial of Keytruda plus chemo met progression-free survival and overall survival goals in platinum-resistant ovarian cancer, including patients with PD-L1–positive tumors.
Immutep Reports 61% Response Rate In Lung Cancer Trial With Keytruda-Based Triple Combo Immutep's efti combo with Keytruda and chemo shows a 60.8% response rate in lung cancer trial, with strong efficacy across PD-L1 expression levels.
Why Pfizer Is Poised For A Strong Comeback: My Top Pick For 2025 For investors willing to look beyond the current negative sentiment, Pfizer at today's prices represents a rare buying opportunity.
CMS Expands Medicare Drug Price Talks To Part B Meds In 2026 Shake Up CMS draft expands drug price talks to include Medicare Part B drugs and outlines steps for future renegotiations; public comments due by June 26.
FDA Approves Merck's Kidney Cancer Drug For Rare Type Of Neuroendocrine Tumors Merck's Welireg wins FDA approval for rare PPGL tumors; Q1 2025 sales reach $137M, marking a 62% year-over-year increase.
Only Half Of S&P 500 Stocks Joined The Tariff-Relief Rally: Time To Buy The Laggards? Only about 50% of S&P 500 stocks trade above their 200-day average, signaling narrow breadth even as the index rallies 22% since April.
